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Abstract The aim of the study was to assess the influence
of white matter lesions in patients with acute ischemic stroke
treated with intra-arterial thrombolysis (IAT). From
September 2003 to January 2010, we treated 400 patients
with IAT at our institution. Of these patients, 292 were
evaluated with MRI scans and included in this observational
study. Clinical data were collected prospectively. Outcome
after 3 months was measured with the modified Rankin
Scale (mRS); mRS 0–1 was considered as favorable out-
come. White matter lesions were scored visually by two
observers using the semiquantitative Scheltens and Fazekas
scores. Logistic regression analysis was used to identify the
association of white matter lesions and clinical outcome,
recanalization, and cerebral hemorrhage. The severity of
white matter lesions was inversely correlated with favorable
outcome, survival and successful recanalization. White
matter lesions were an independent predictor of outcome
(OR 0.569, p = 0.007) and survival (OR 0.550, p = 0.018)
and a weak but independent predictor for recanalization (OR
0.949, p = 0.038). Asymptomatic intracerebral bleeding
after IAT was associated with white matter lesions in the
basal ganglia in the univariate analysis (p = 0.036), but not
after multivariable analysis. The severity of white matter
lesions independently predicts clinical outcome and survival
in patients treated with IAT. White matter lesions are also a
weak but independent predictor for recanalization. Symp-
tomatic intracranial bleeding after IAT are not associated
with white matter lesions. Therefore, white matter lesions
should not be considered as a contraindication against IAT.
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Introduction
Lesions that comprise periventricular, deep and subcortical
white matter attracted great attention since French reports in
the nineteenth century and since Otto Binswanger’s German
report in 1894. The advent of cerebral imaging rekindled
this interest, first the hypodensities of the white matter seen
on computed tomography and later the impressive hyper-
intensities visible on T2-weighted magnetic resonance
imaging (MRI). Today, we know that the periventricular,
deep and subcortical T2-hyperintensities on MRI are non-
specific. Therefore, white matter lesions have also received
the term leukoaraiosis. White matter lesions are a sign of
ischemic damage due to various small vessel diseases,
dilated perivascular spaces, or lacunar infarcts. Several
factors were identified that influence the severity of these
white matter lesions. The strongest association was found
for increasing age and hypertension [1, 2]. Other factors
such as diabetes mellitus, atherosclerosis, hyperlipidemia,
hyperhomocysteinemia, and smoking were also identified
as risk factors, but with weaker associations. Furthermore,
genetic background seems to play a role. The distribution of
white matter lesions within the brain is not even; in general
white matter lesions are more pronounced in anterior
compared to posterior brain regions [3].
S. Jung  M. L. Mono  O. Findling  U. Fischer 
A. Galimanis  A. Weck  G. M. De Marchis  P. Ballinari 
M. Arnold  H. P. Mattle (&)
Department of Neurology, Inselspital, University Hospital Bern,
University of Bern, Freiburgstrasse 10, 3010 Bern, Switzerland
e-mail: heinrich.mattle@insel.ch
J. Gralla  C. Brekenfeld  G. Schroth  M. El-Koussy
Department of Neuroradiology, Inselspital, University Hospital
Bern, University of Bern, Freiburgstrasse 10,
3010 Bern, Switzerland
123
J Neurol (2012) 259:1331–1336
DOI 10.1007/s00415-011-6352-y
White matter lesions represent an independent risk
factor for stroke [4] and predict unfavorable outcome after
stroke [5]. There is a major concern that white matter
lesions affect outcome in patients with acute ischemic
stroke: three studies showed that patients with white matter
lesions have a greater risk of intracranial hemorrhage after
intravenous thrombolysis [6–8]. Because of the association
with outcome and bleeding complications, white matter
lesions have become an issue for treating physicians. The
aim of the present study was to evaluate the predictive
value of white matter lesions and their regional distribution
for outcome and complications of IAT for acute ischemic
stroke.
Patients and methods
From September 2003 to January 2010, 400 patients were
treated with IAT for acute stroke in our Stroke Unit.
Patients who were examined with MRI scans of the brain
within 30 days from stroke onset were selected for this
study (n = 292) but not patients examined with CT scans
(n = 103) or inadequate MR image quality (n = 5).
Clinical data
All patients were examined immediately after admission by
a neurologist and the neurologic deficit was scored using
the National Institutes of Health Stroke Scale (NIHSS) [9].
Demographic data, time of symptom onset, and previous
medical history (prestroke handicap, history of coronary
artery disease, atrial fibrillation, transient ischemic attack
(TIA) ischemic stroke) and stroke risk factors such as sex,
hypertension, diabetes, current cigarette smoking, hyper-
cholesterolemia, coronary heart disease, and a family his-
tory of TIA and stroke were recorded. Digital substraction
angiography was performed via a transfemoral approach
using a biplane, high-resolution angiography system. All
patients underwent complete four-vessel cerebral angiog-
raphy to assess vessel occlusions and collateral flow. The
site of artery occlusion was categorized as follows: proxi-
mal and distal internal carotid artery, carotid-T, M1/M2/
M3–4 segments of the middle cerebral artery, A1/A2 seg-
ments of the anterior cerebral artery, P1/P2 segments of the
posterior cerebral artery, proximal/mid/distal segments of
the basilar artery, and the vertebral artery. Collaterals were
graded as reported previously [10].
The interventional neuroradiologists decided on the use
of urokinase, mechanical intervention, or both as recana-
lization techniques. At the end of the angiography, recan-
alization was classified according to thrombolysis in
myocardial infarction (TIMI) grades [11]: 1, minimal
recanalization; 2, partial and 3, complete recanalization.
A computed tomography (CT) or MRI scan was
obtained to assess bleeding complications 24–72 h after
treatment. Symptomatic (sICH) and asymptomatic intra-
cerebral bleedings (aICH) were scored according to the
PROACT II Study [12].
The etiology of the stroke was classified according to the
TOAST criteria using ancillary investigations as necessary
[13]. Secondary preventive treatment was given according
to European guidelines [14, 15].
Medium-term outcome was assessed 3 months after
stroke using the modified Rankin scale (mRS) [16]. The
follow-up information was obtained by clinical examina-
tions in 78.5% of the patients or by structured telephone
interviews in 21.5%.
Imaging methods
MRI was performed using a 1.5 T MR imaging system
(Magnetom, Siemens). We used axial T1 (TR 2,000 ms,
TE 40 ms), T2 (TR 2,000 ms, TE 50 ms), proton density
(TR 5,000 ms, TE 96 ms), and diffusion-weighted imaging
(TR 3,200 ms, TE 87 ms), with automatic calculation of
the apparent diffusion coefficient (ADC maps).
Imaging analysis
Slice thickness was 5 mm. White matter lesions were
scored using two different visual scoring systems. With the
scoring system of Fazekas and Schmidt [17] periventricular
hyperintensities (Fazekas PV) were graded as follows: if
absent as 0, caps or pencil-thin lining as 1, smooth halo as 2,
and irregular periventricular white matter lesions extending
into the deep white matter as 3. Subcortical and deep white
matter lesions (Fazekas WM) were scored as follows:
absent as 0, punctate foci as 1, a beginning confluence of
foci as 2, and large confluent areas as 3. The second scoring
system used was the Scheltens score [18]. The periven-
tricular region (Scheltens PV) was divided into the frontal
caps, occipital caps and the bands in between the caps. Each
region was separately scored as follows: absent as 0, white
matter lesions up to 5 mm as 1 and larger than 5 mm as 2.
Accordingly, the deep white matter (Scheltens WM) was
divided into frontal, parietal, occipital, and temporal
regions. The basal ganglia (Scheltens BG) were divided into
caudate nucleus, putamen, globus pallidus, thalamus, and
internal capsule. Each of these regions was scored as fol-
lows: absent as 0, \6 lesions with a diameter smaller than
3 mm as 1,[5 lesions with a diameter smaller than 3 mm as
2,\6 lesions with a diameter of 4–10 mm as 3,[5 lesions
with a diameter of 4–10 mm as 4, at least one lesion
[10 mm diameter as 5, and confluent lesions as 6.
Scores for Scheltens PV, WM, and BG were calculated
by summation of the different regions. All MRI scans were
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scored jointly by two examiners (S.J. and M. E.-K.) blinded
to clinical data. Whenever they scored differently, the
grade was decided by consensus.
Statistical analysis
Statistical analysis was performed using SPSS 18 (SPSS
Inc., Chicago, IL, USA). Forward stepwise logistic regres-
sion analysis was carried out on the predictive factors
identified by univariate analysis [v2 test or for continuous
variables Mann–Whitney test with p \ 0.2; considering
age, gender, time to thrombolysis, NIHSS score on admis-
sion, TOAST classification, diabetes mellitus, hypertension,
hypercholesterolemia, atrial fibrillation, artery dissection,
coronary artery disease, previous stroke, previous use of
antithrombotic therapy, smoking, family history of stroke,
occlusion type, collaterals, TIMI grade after therapy,
Fazekas sum score, Scheltens sum score, and scores of the
subregions (PV, WM, BG)]. Predictors of outcome were
analyzed by comparing patients with a favorable clinical
outcome (mRS 0–1) and those with a less favorable out-
come (mRS 2–6). Predictors of survival were analyzed by
comparing stroke survivors (mRS 0–5) and patients who
died (mRS 6) within 3 months after the stroke. Predictors of
recanalization were analyzed by comparing poor (TIMI
0–1) and good (TIMI 2–3) recanalization. Predictors of
intracerebral bleeding after thrombolysis were analyzed by
comparing patients with sICH or aICH and those without
hemorrhage.
Results
A total of 292 patients had MRI scans within 30 days from
stroke onset and were included in this study; 229 (78.4%)
of the 292 MRI scans were obtained on the day of symptom
onset, 63 (21.6%) within 26 days of stroke onset.
The baseline characteristics, treatment, outcome, and
complications are summarized in Table 1. Twenty-eight
(9.6%) of the 292 patients were older than 80 years. Follow-
up was obtained from 289 patients (99%), from 227 (77.7%)
by clinical examination, and from 62 (22.3%) by phone
interview. Prior to stroke, 291 patients were independent.
Results of white matter lesion scoring with the Fazekas
and Scheltens scores in relation to outcome are given in
Table 2. Mean values of the sum scores of each brain
region are given.
Predictors of outcome and survival
In multivariate logistic regression analysis lower age, lower
baseline NIHSS, shorter time to treatment, absence of
diabetes mellitus, good collaterals as seen on digital
Table 1 Baseline characteristics, treatment, outcome, and compli-
cations of 292 patients with acute ischemic stroke
N (%)a
Baseline characteristics and treatment
Age, years (standard deviation) 64 (15)
Female sex 161 (44.9)
Vascular risk factors
Hypertension 171 (58.6)
Diabetes mellitus 45 (15.4)
Current smoking (n = 290) 65 (22.4)
Hypercholesterolemia 161 (55.1)
Coronary artery disease 43 (14.7)
Atrial fibrillation (n = 290) 86 (29.7)
Previous stroke 20 (6.8)
Family history of stroke (n = 281) 39 (13.9)
Previous ASS/OAC 100 (34.2)
Stroke etiology
Large artery disease 58 (19.9)
Cardioembolic 126 (43.2)
Other determined etiology 37 (12.7)
Unknown etiology 70 (23.9)
Dissection 12 (4.1)
Baseline NIHSS score, median (range) 15 (2–36)
Occlusion localization
Internal carotid artery 44 (15.1)
Carotid T 28 (9.6)
Anterior cerebral artery 1 (0.3)
Middle cerebral artery 160 (4.8)
Posterior cerebral artery 3 (1.0)
Basilar artery 55 (18.8)
Vertebral artery 1 (0.3)
Intraarterial thrombolysis type
Urokinase only 237 (1.2)
Bridging IVT and IAT 9 (3.1)
Mechanical only 46 (15.8)
Minutes from symptom onset to treatment,
median (range)
286 (82–1,440)
Urokinase dose, median IE (range) 1,000,000
(0–1,500,000)
Outcome parameters
mRS 0–1 (n = 289) 76 (26.3)
Survival (n = 289) 226 (77.4)
Recanalization grade
TIMI 0 59 (20.2)
TIMI 1 19 (6.5)
TIMI 2 58 (19.9)
TIMI 3 156 (53.4)
Bleeding complications
sICH 12 (4.1)
aICH 70 (24.0)
a Number and percent of patients unless stated otherwise
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subtraction angiography and recanalization TIMI 2 or 3
were identified as independent predictors for favorable
clinical outcome (mRS 0–1) (Table 3). When Fazekas,
Scheltens, Fazekas PV, Fazekas WM, Scheltens PV,
Scheltens WM, and Scheltens BG scores were added sep-
arately into the model, Fazekas PV, Scheltens PV, and
Fazekas turned out as independent predictors and replaced
the factor age. Younger age, low NIHSS on admission, and
good collaterals on arteriography independently predicted
survival. In addition, Fazekas PV or Scheltens PV inde-
pendently predicted survival.
Predictors of recanalization
Younger age and shorter time to treatment were indepen-
dent predictors of recanalization after IAT (Table 3). When
white matter lesion scores were added into the multivariate
model, the Scheltens score turned out to be weakly pre-
dictive in exchange for the factor age.
Predictors of hemorrhage
Atrial fibrillation was identified as independent predictors
for aICH, but not white matter lesion severity. A trend was
seen for Fazekas (p = 0.265) and Scheltens BG
(p = 0.152) scores. Asymptomatic hemorrhages were
associated with the Scheltens BG (p = 0.036) score in
univariate analysis, but showed only a trend in multivariate
analysis (p = 0.138). Potentially due to the small sample
size no predictors could be identified for sICH.
All these results were consistent with only minor
changes in p values when the 9 patients treated with
combined IVT and IAT were excluded from the model or
when only patients with MRI on the admission day were
included in a separate analysis (data not shown).
Discussion
The main finding of our study is that less severe periven-
tricular white matter lesions in patients treated with IAT for
Table 2 Mean white matter lesion scores and outcome, two-tailed significance levels in brackets
Fazekas Scheltens Fazekas peri-
ventricular
Fazekas white
matter
Scheltens peri-
ventricular
Scheltens white
matter
Scheltens basal
ganglia
mRS 0–1 1.46 (0.003) 4.43 (0.033) 0.63 (0.001) 0.83 (0.061) 1.01 (0.001) 2.88 (0.091) 0.54 (0.493)
mRS 2–6 1.97 6.03 0.98 0.99 1.64 3.70 0.69
Survival 1.68 (<0.001) 5.05 (0.001) 0.77 (<0.001) 0.90 (0.023) 1.26 (<0.001) 3.19 (0.008) 0.60 (0.36)
Death 2.40 7.62 1.29 1.11 2.25 4.56 0.81
Recanalization
TIMI 2 ? 3
1.77 (0.095) 5.11 (0.011) 0.85 (0.109) 0.92 (0.168) 1.37 (0.034) 3.20 (0.02) 0.55 (0.094)
Recanalization
TIMI 0 ? 1
2.05 6.99 1.01 1.04 1.78 4.31 0.90
sICH 1.92 (0.839) 5.08 (0.738) 0.92 (0.906) 1.00 (0.793) 1.50 (0.961) 3.00 (0.632) 0.58 (0.899)
No sICH 1.84 5.64 0.89 0.95 1.48 3.51 0.64
aICH 1.90 (0.67) 5.79 (0.767) 0.94 (0.524) 0.96 (0.94) 1.47 (0.959) 3.39 (0.777) 0.93 (0.081)
No aICH 1.82 5.56 0.87 0.95 1.48 3.53 0.55
Bold values are statistically significant at p \ 0.05
Table 3 Multivariate logistic regression analysis: independent pre-
dictors for outcome, survival, and recanalization
p OR 95% CI
Dependent variable outcome (mRS 0–1 vs. 2–6)
NIHSS \0.0001 0.878 0.832–0.926
Collaterals 0.017 2.845 1.210–6.689
Time to treatment 0.039 0.996 0.992–1.000
Diabetes mellitus 0.026 0.274 0.088–0.856
Recanalization 0.021 2.542 1.148–5.629
Fazekas PV 0.007 0.569 0.379–0.856
Fazekas 0.021
Scheltens 0.062
Scheltens PV 0.011
Dependent variable survival
NIHSS \0.0001 0.886 0.849–0.925
Collaterals \0.0001 5.370 2.597–11.105
Age 0.004 0.947 0.913–0.983
Fazekas PV 0.018 0.550 0.335–0.904
Fazekas 0.107
Scheltens 0.067
Scheltens PV 0.014
Dependent variable recanalization
Time to treatment 0.037 0.997 0.995–1.000
Scheltens 0.011 0.944 0.902–0.987
Dependent variable aICH
Atrial fibrillation 0.005 2.236 1.273–3.928
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acute stroke independently predicted favorable clinical
outcome and survival. In addition, better recanalization
occurred when there were less severe white matter lesions
of the whole brain. The presence of white matter lesions in
the basal ganglia region was associated with asymptomatic
intracerebral bleedings in univariate but not in multivariate
analysis.
White matter lesions have been identified as a risk factor
for future strokes [1, 3, 4] and as a predictor of unfavorable
outcome in the spontaneous course of stroke [5, 19–23]. To
date, the role of white matter lesions in patients treated
with IVT for acute stroke is not clear. Using CT for
assessment of white matter lesions, Arie¨s and co-workers
[24] identified them as an independent predictor of poor
functional outcome (p = 0.01, OR 2.39, 95% CI
1.21–4.72) in patients treated with IVT, while other authors
did not find any association [6, 25]. The poor sensitivity of
CT to detect white matter lesions in comparison to MRI
might account for these conflicting results in IVT studies.
Our study assessed white matter lesions with MRI and
addressed their influence on outcome and survival after
acute stroke treated with IAT. It shows that the severity of
pre-existing white matter lesions is an important predictor
for both functional outcome and survival. Furthermore,
their regional distribution within the brain may be critical
for outcome as well. Both the Fazekas and the Scheltens
scores revealed white matter lesions in the periventricular
region to be most predictive for clinical outcome and
survival.
In addition, white matter lesions turned out to predict
recanalization independently, though with a smaller odds
ratio than for clinical outcome and survival. This interest-
ing observation might be explained by the coexistence of
small and large vessel disease. Patients with small vessel
disease are more likely to also suffer from large vessel
disease [26, 27].
In the multivariate analysis, white matter lesions com-
pete with the factor age in predicting outcome and recan-
alization. This phenomenon has already been previously
observed [7, 23]. Because age and hypertension are the
most important predictors of white matter lesions, this
finding is not unexpected. Potentially the severity of white
matter lesions is a more precise predictor of outcome and
survival than age, but this question has to be corroborated
by further studies including more patients.
While one study with a mixed IVT and IAT [7] and two
studies with an IVT population [6, 8] found white matter
lesions to be independently predictive for sICH after IVT,
one IVT study did not [24]. In our IAT series, there was no
independent association of white matter lesions and sICH.
White matter lesions were associated with asymptomatic
ICH only in univariate analysis, but not after multivariable
analysis and there was no association with symptomatic
bleedings. This might be explained by the low number of
sICH in our series and the differing definitions of sICH that
are used in the different studies. However, the current
practical implication might be that white matter lesions
may not be considered as a contraindication to IAT. When
symptomatic intracranial bleeding after IAT occurs, it is
most likely not caused by white matter lesions.
Our study has several limitations. It is a single center
non-randomized study with a potential selection bias.
Another potential limitation is the visual scoring of white
matter lesions, which is less accurate than volumetry [28].
On the other hand, volumetry of white matter lesions
showed a nonlinear relationship between the Fazekas and
Scheltens scores indicating that visual scoring is a valid
method as well.
Summary
White matter lesions are a radiological sign easily visible
on the widely available conventional MRI sequences. Our
results show that white matter lesions in patients treated
with IAT are independently predictive of outcome,
mortality, and recanalization. Their severity is inversely
correlated with favorable outcome, survival, and good
recanalization. The severity of white matter lesions is also
correlated with age and might be even a better prognostic
indicator than age. Symptomatic intracranial bleeding after
IAT are not associated with white matter lesions. There-
fore, white matter lesions should not be considered as a
contraindication against IAT.
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